The Urothelial Transcriptomic Response to Interferon Gamma: Implications for Bladder Cancer Prognosis and Immunotherapy.

Baker, Simon C; Mason, Andrew S; Slip, Raphael G; Eriksson, Pontus; Sjödahl, Gottfrid; Trejdosiewicz, Ludwik K; Southgate, Jennifer

Baker, Simon C; Mason, Andrew S; Slip, Raphael G; Eriksson, Pontus; Sjödahl, Gottfrid; Trejdosiewicz, Ludwik K; Southgate, Jennifer.

Affiliation

Baker SC; Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK.
Mason AS; Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK.
Slip RG; Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK.
Eriksson P; Division of Oncology, Department of Clinical Sciences Lund, Lund University, 22184 Lund, Sweden.
Sjödahl G; Department of Translational Medicine, Lund University, 20502 Malmö, Sweden.
Trejdosiewicz LK; Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK.
Southgate J; Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK.

Cancers (Basel) ; 14(21)2022 Oct 27.

Article de En | MEDLINE | ID: mdl-36358715

Mots clés

BCG; PD-L1; VISTA; bladder cancer; immune checkpoint; immunotherapy; interferon gamma; urothelium

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Cancers (Basel) Année: 2022 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google